Medtronic Announces FDA Approval of EnRhythm Pacemaker

Medtronic announced FDA approval and subsequent U.S. launch of the dual-chamber EnRhythm pacemaker, which promotes natural heart activity by significantly reducing unnecessary pacing in the heart's right ventricle (lower chamber).

Clinical studies have shown that unnecessary pacing in the right ventricle can increase the risk for heart failure and atrial fibrillation. The EnRhythm device is the first-ever pacemaker to offer an exclusive pacing mode called MVP (managed ventricular pacing), which enables the device to be programmed to deliver pacing pulses to the right ventricle less than 2 percent of the time.

The EnRhythm pacemaker also offers Atrial Reactive ATP (anti-tachycardia pacing), a feature enabling the device to continually search for opportunities to restore a patient's normal sinus rhythm during long, fast heart rhythm episodes in the atrium. EnRhythm is one element of Medtronic's Physiologic Pacing Program, a comprehensive initiative focused on providing tailored solutions to promote or mimic a patient's normal cardiac function.